In this updated analysis of patients with PD-/PD-L1–treated metastatic cutaneous melanoma, tebentafusp, a bispecific therapy targeting gp100 and CD3, plus anti–PD-L1 was associated with a promising 1-year OS rate of 75%.
PRADO confirmed high pathologic response rates with neoadjuvant ipilimumab + nivolumab in stage III melanoma and demonstrated good outcomes in patients with major pathologic responses not receiving therapeutic lymph node dissection and adjuvant therapy
In patients with locally advanced desmoplastic melanoma, neoadjuvant pembrolizumab was associated with a pathologic CR rate of 55% and led to no toxicity-related surgery cancellations.
Concurrent neoadjuvant dabrafenib and trametinib and pembrolizumab resulted in high pathologic response rate in patients with stage III melanoma, although with increased toxicity compared with sequential regimen or pembrolizumab monotherapy.
Relatlimab + nivolumab was favored over nivolumab alone across key subgroups for PFS, OS, and ORR in previously untreated patients with advanced melanoma.
A triplet combination of camrelizumab (anti–PD-1), apatinib (VEGFR-2–targeted TKI), and temozolomide showed promising antitumor activity and manageable toxicity in previously untreated advanced acral melanoma.
In the phase I AMBER trial, the anti–TIM-3 mAb cobolimab combined with dostarlimab showed a manageable safety profile in patients with advanced solid tumors and preliminary antitumor activity in patients with advanced melanoma.
The combination of atezolizumab, cobimetinib, and vemurafenib showed promising intracranial activity in advanced BRAFV600-mutated melanoma with CNS metastases.
With 7.5-year follow-up, the phase III CheckMate 067 trial continued to demonstrate durable survival benefits with first-line nivolumab + ipilimumab in patients with advanced melanoma.
Results through 27.4 months of follow-up continue to support the benefit of adjuvant pembrolizumab in reducing the risk of recurrence and distant metastasis in patients with stage IIB/IIC melanoma.